
Unmet Needs
Understanding crucial unmet needs and identifying opportunities in drug development with a focus on specific indications and insights into how well current or emerging therapies are poised to meet them.
Formerly known as BioTrends, we use our deep therapeutic expertise, layered onto data-driven insights, to support product success throughout the entire commercialization cycle. We provide our customers with brand trends & insights by using brand-centric market research. This research allows us to address not only the performance of brands and competitors in the marketplace, but also treatment decision drivers, including physician perception, awareness, and uptake.
Our innovative insights uncover the why, what, and how of brand performance
Understanding crucial unmet needs and identifying opportunities in drug development with a focus on specific indications and insights into how well current or emerging therapies are poised to meet them.
Our solutions combine resolution physician network analysis with quantifiable payer and health system influence to identify the most influential physicians and institutions that are likely to have the highest impact on a community of practice.
Our blend of clinical development experience, internal market planning tools, and therapeutic expertise uniquely positions our team to support the product development process.
Coming Soon – November 2019 MARKET OUTLOOK Biomarker-driven prescribing...
Coming soon – April 2019 MARKET OUTLOOK Clinical pathways, which...
Coming Soon – April 2019 Premium-priced therapies in ovarian cancer,...
Coming soon – December 2019 MARKET OUTLOOK As part of ongoing efforts to...
Coming Soon – March 2019 Pharmacotherapy for adult asthma has two main...
In the bid to break the non-alcoholic steatohepatitis (NASH) market, a two-horse race to be first-to-market emerged between Gilead...
In DRG Blog, Drug Watch / Feb, 2019
Too often, we hear from brands that invested substantially in building patient websites --...
In DRG Blog, Drug Watch, Digital Innovation / Feb, 2019
On 23 September 2018, India’s Prime Minister Narendra Modi announced the launch of the National Health Protection Scheme or “...
In DRG Blog, Drug Watch, Digital Innovation / Feb, 2019
A history of Evenity's development, and the wider implications of the FDA advisory committee's decision to recommend the approval...
In DRG Blog, Drug Watch, Digital Innovation / Feb, 2019
Why is the change being made? Across India, there has been a historical lack of access to quality health care, caused primarily by...
In DRG Blog, Drug Watch, Digital Innovation, MedTech / Feb, 2019
In the news
News articles citing DRG analysts data.
Feb 12, 2019
Feb 12, 2019
Jan 31, 2019
Jan 22, 2019